Abiraterone acetate - Johnson & Johnson

Drug Profile

Abiraterone acetate - Johnson & Johnson

Alternative Names: Abirateron-acetate-fine-particles; Aviraterone acetate; CB-7630; JNJ-212082; Zaitiga; Zaytiga; Zitiga; Zytiga

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Institute of Cancer Research
  • Developer All Ireland Cooperative Oncology Research Group; Assistance Publique Hopitaux de Paris; Cancer Research UK; Cougar Biotechnology; Janssen Research & Development; Johnson & Johnson; UNICANCER
  • Class Androstenols; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Breast cancer; Ovarian cancer
  • No development reported Congenital adrenal hyperplasia

Most Recent Events

  • 26 Jun 2018 Phase-II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in France (PO) (NCT03458247)
  • 06 Jun 2018 The National Institute for Health and Clinical Excellence does not recommend abiraterone for Prostate cancer (Combination therapy, First-line therapy, Hormone refractory, Metastatic disease)
  • 05 Jun 2018 Janssen Pharmaceutica completes a phase II trial for Prostate cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Belgium, Germany, Hungary, Italy, United Kingdom (PO) (NCT01867710)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top